Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Ironwood Pharmaceuticals stock
Learn how to easily invest in Ironwood Pharmaceuticals stock.
Ironwood Pharmaceuticals is a drug manufacturers-specialty & generic business based in the US. Ironwood Pharmaceuticals shares (IRWD) are listed on the NASDAQ and all prices are listed in US Dollars. Ironwood Pharmaceuticals employs 219 staff and has a trailing 12-month revenue of around $420.5 million.
How to buy Ironwood Pharmaceuticals stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – IRWD. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
What's in this guide?
- IRWD shares summary
- Compare share dealing platforms
- Is IRWD stock a buy or sell?
- Stock performance over time
- Are IRWD shares over-valued?
- Ironwood Pharmaceuticals's financials
- How volatile are IRWD shares?
- Does Ironwood Pharmaceuticals pay a dividend?
- Have IRWD shares ever split?
- Other common questions
Ironwood Pharmaceuticals stock price (NASDAQ: IRWD)Use our graph to track the performance of IRWD stocks over time.
Ironwood Pharmaceuticals shares at a glance
|Latest market close||$11.31|
|52-week range||$9.73 - $12.95|
|50-day moving average||$11.84|
|200-day moving average||$11.48|
|Wall St. target price||$13.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.93|
Buy Ironwood Pharmaceuticals stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Ironwood Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Ironwood Pharmaceuticals price performance over time
|1 week (2023-01-20)||-0.88%|
|1 month (2022-12-27)||-7.30%|
|3 months (2022-10-27)||3.67%|
|6 months (2022-07-27)||-8.50%|
|1 year (2022-01-26)||4.24%|
|2 years (2021-01-27)||8.85%|
|3 years (2020-01-27)||12.18|
|5 years (2018-01-26)||16.2702|
Is Ironwood Pharmaceuticals stock undervalued or overvalued?
Valuing Ironwood Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ironwood Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ironwood Pharmaceuticals's P/E ratio
Ironwood Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Ironwood Pharmaceuticals shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Ironwood Pharmaceuticals's EBITDA
Ironwood Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $240.3 million.
The EBITDA is a measure of a Ironwood Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Ironwood Pharmaceuticals financials
|Revenue TTM||$420.5 million|
|Operating margin TTM||56.8%|
|Gross profit TTM||$343.3 million|
|Return on assets TTM||14.09%|
|Return on equity TTM||28.62%|
|Market capitalisation||$1.8 billion|
TTM: trailing 12 months
Ironwood Pharmaceuticals share dividends
We're not expecting Ironwood Pharmaceuticals to pay a dividend over the next 12 months.
Have Ironwood Pharmaceuticals's shares ever split?
Ironwood Pharmaceuticals's shares were split on a 1194:1000 basis on 1 April 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1194 shares. This wouldn't directly have changed the overall worth of your Ironwood Pharmaceuticals shares – just the quantity. However, indirectly, the new 16.2% lower share price could have impacted the market appetite for Ironwood Pharmaceuticals shares which in turn could have impacted Ironwood Pharmaceuticals's share price.
Ironwood Pharmaceuticals share price volatility
Over the last 12 months, Ironwood Pharmaceuticals's shares have ranged in value from as little as $9.73 up to $12.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ironwood Pharmaceuticals's is 0.9487. This would suggest that Ironwood Pharmaceuticals's shares are less volatile than average (for this exchange).
Ironwood Pharmaceuticals overview
Ironwood Pharmaceuticals, Inc. , a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc. , AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
Ironwood Pharmaceuticals in the news
12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds
Ironwood Pharmaceuticals (NASDAQ:IRWD) shareholders are up 3.7% this past week, but still in the red over the last five years
Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
Frequently asked questionsWhat percentage of Ironwood Pharmaceuticals is owned by insiders or institutions?
Currently 1.54% of Ironwood Pharmaceuticals shares are held by insiders and 115.657% by institutions. How many people work for Ironwood Pharmaceuticals?
Latest data suggests 219 work at Ironwood Pharmaceuticals. When does the fiscal year end for Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals's fiscal year ends in December. Where is Ironwood Pharmaceuticals based?
Ironwood Pharmaceuticals's address is: 100 Summer Street, Boston, MA, United States, 02110 What is Ironwood Pharmaceuticals's ISIN number?
Ironwood Pharmaceuticals's international securities identification number is: US46333X1081 What is Ironwood Pharmaceuticals's CUSIP number?
Ironwood Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 46333X108
More guides on Finder
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert